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Abstract  
· Objectives -To investigate the most efficient use of echocardiography and natriuretic 
peptide testing in the diagnosis of heart failure. 
· Design - An economic model comparing two strategies: (A) provide echocardiography 
and electrocardiogram (ECG) for all individuals who present to a GP with symptoms that 
may be due to heart failure; (B) carry out B-type natriuretic peptide (BNP) blood test and 
ECG on all such individuals and provide echocardiography only where an abnormality is 
detected in one of more of these tests.  
· Setting - Primary care in the UK NHS.  
· Subjects - Individuals who present to a GP with new symptoms of heart failure.  
· Main outcome measures - Cost per life year gained.  
· Results – Baseline cost per life year gained by strategy A compared with strategy B is 
£3,987.  
· Conclusions – Immediate echocardiography is the most cost-effective option.  Where 
echocardiography is a scarce resource, efficient use can be obtained by using BNP and 
ECG tests to identify patients most likely to have heart failure.   
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Introduction 
Around 900 000 people in the UK today have heart failure.1 The condition has a poor prognosis: 
just under 40% of patients diagnosed with heart failure die within a year – but thereafter the 
mortality is less than 10% per year2.  Heart failure accounts for 2% of all NHS inpatient bed-days 
and 5% of all emergency medical admissions to hospital.1,3  
 
The mainstay of treatment of heart failure is drug therapy – typically with diuretics, ACE 
inhibitors and beta-blockers, in addition to various lifestyle measures such as avoiding salty foods, 
taking regular exercise, and monitoring any weight gain that might suggest fluid retention. Such 
treatment lengthens life, improves symptoms, and reduces the need for emergency 
hospitalisation.4,5 Access to these treatments requires efficient diagnosis of the condition.   There 
is no ‘gold standard’ for the diagnosis of heart failure, which is a constellation of different 
symptoms due to underlying cardiac dysfunction. Many studies have reported that the accuracy 
of the diagnosis of heart failure is poor in primary care, particularly when there is low usage of 
echocardiography, which can confirm the presence of underlying cardiac dysfunction.  
 
Echocardiography is a limited resource in the UK, chiefly because of lack of trained 
echocardiographers. Heart failure is very unlikely in a patient with a normal 12-lead 
electrocardiogram ECG6,7,8 or low plasma B-type natriuretic peptide (BNP) concentration, given 
the high sensitivity of these tests. 9,10,11,12,13,14  Normal results may, therefore, be useful in guiding 
the doctor to consider other diagnoses and investigations. This paper investigates the cost-
effectiveness of routine echocardiography and ECG for all patients presenting to a GP with 
suspected heart failure (strategy A), compared with a filtering strategy of initial testing by 
measurement of plasma BNP concentration and ECG, followed by an echocardiogram only 
when an abnormality is suggested by one or more of the tests (strategy B), as recommended by 
the National Institute for Clinical Excellence (NICE) in the chronic heart failure guideline 
published in 2003.4  
Methods  
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Our cost effectiveness analysis is based on a model that traces a hypothetical cohort of 100 adults 
who present to the GP with possible symptoms of heart failure. The two strategies previously 
defined are compared in terms of the direct NHS costs and patient outcomes over a period of 
five years from diagnosis.  
A model schematic is shown in Figure 1, illustrating the basic structure and key parameters at 
each stage. Table 1 provides the baseline values and data sources for the key parameters, as well 
the values used in sensitivity analysis.   
Prevalence of heart failure in this population  
This is an estimate of the proportion of people referred for testing by a GP who receive a 
diagnosis of heart failure after further investigation. The baseline estimate of 29% comes from 
the Hillingdon Heart Failure study, where 81 GPs referred all suspected new cases of heart failure 
to a rapid access study clinic. 9,15 The GPs in the Hillingdon study may have had higher than 
average awareness of the condition: for sensitivity analysis our lower estimate (18%) is taken 
from a study of an open access echocardiography service, 16 and our upper estimate (34%) comes 
from other empirical studies of diagnosing heart failure in patients referred from primary care. 17,18   
 
Sensitivity and specificity of tests 
Echocardiography is assumed to be the diagnostic ‘gold standard’ – we assume that after such 
investigation all patients are correctly diagnosed as heart failure or not. This is obviously an 
oversimplification, although in practice most diagnostic services function so that history, clinical 
examination, and echocardiography are all that is required to confirm or refute a diagnosis of 
heart failure. Such an assumption implies that echocardiography is both 100% sensitive and 
specific. Hence in the model, there are no false positives because any abnormality detected by 
BNP or ECG will be referred for echocardiogram and as this is assumed to give a definitive 
diagnosis it will pick up any false positives from the first stage. The sensitivity of BNP and ECG 
will determine the number of missed cases and we assume that missed diagnoses are not re-
diagnosed within the five year period considered.  
The baseline figures for sensitivity and specificity of BNP plus ECG (0.94 and 0.44 respectively) 
are taken from the recently published UK BNP study.17 These figures were found using a 
decision cut-point for plasma BNP level of 65 pg/ml and any abnormality on the resting ECG. 
The upper and lower 95% confidence intervals, calculated from the raw data were used in the 
sensitivity analyses.  
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In the base case strategy B requires 67.02 echocardiographs, 27.26 in patients with heart failure 
and 39.76 in patients without heart failure. This represents 94% and 56% of the relevant 
population respectively. 
Costs 
All costs are reported in 2003 Sterling.  Costs of each strategy include the costs of the tests, costs 
of drug treatment for heart failure and the hospitalisation costs for heart failure admissions. The 
costs for 12 lead ECG and echocardiogram were obtained from NHS Reference Costs 200319. 
The range of values for these costs are particularly uncertain and vary substantially according to 
whether the tests are carried out as an outpatient appointment or via a direct access arrangement. 
The baseline costs are the average of the direct access and outpatient costs. For the sensitivity 
analysis the lower limit is zero and the upper limit is twice the baseline. The cost of a BNP test 
was obtained from the manufacturers. The average cost of an inpatient bed day for heart failure 
and average length of stay for heart failure are taken from NHS Reference Costs 2003.  
Costs of treatment with ACE inhibitors and beta-blockers are calculated from the British 
National Formulary according to target doses recommended in the NICE guideline. 4 Baseline 
costs are for mid price brands and sensitivity analysis considers the lowest cost generics and the 
most expensive brands. We also include the costs of tests carried out during initiation and 
titration of treatment, assuming this involves an average of three blood biochemistry tests. 19 Since 
both beta-blockers and ACE inhibitors are increasingly used to treat other conditions, we assume 
that a proportion of the cohort will already be taking these drugs prior to a heart failure 
diagnosis.  
Outcomes 
Outcomes are expressed in terms of life years gained from treatment, assuming that a diagnosis 
of heart failure means access to treatment that is not available to people who do not have a 
confirmed diagnosis. For simplicity it is assumed that everyone who has a diagnosis of heart 
failure is eligible for treatment with an ACE inhibitor and beta-blocker. Treatment with these 
agents is known to have a beneficial effect in terms of life expectancy and reduced hospitalisation 
in randomised clinical trials, and this benefit is assumed to continue over the five-year period 
considered. Whilst it is possible that treatment has benefits in terms of quality of life, another 
metric of cost-effectiveness, these are not considered here due to a lack of available data. 
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The Hillingdon cohort provides cumulative survival probabilities for people with heart failure 
who are treated with ACE inhibitors.15 Beta-blocker treatment was rare in this cohort, due to the 
timing of the study. Treatment benefits from ACE inhibitors and beta-blockers in terms of life 
years gained and hospitalisation are taken from meta-analyses of randomised controlled trials. 
Since these trials generally include patients who have already had a diagnosis of heart failure for 
around 12 to 18 months prior to the trial start, we use data from trials of patients who receive 
ACE inhibitors for the treatment of heart failure after MI to estimate treatment benefits in the 
first year following diagnosis.20,21,22 This information is used to adjust the Hillingdon probabilities 
so that we estimate outcomes for an untreated cohort and for treatment with the combination of 
ACE inhibitors and beta-blockers. Cumulative survival probabilities for people who present with 
possible symptoms but who do not receive a diagnosis of heart failure after further investigation 
are also taken from the Hillingdon study.    
Discounting 
As the costs and outcomes in this model accrue over 5 years, discounting is used to give less 
weight to those that occur in the future compared with those that occur in the present. In 
keeping with recommendations from NICE23 we discount both costs and benefits at 3.5% and 
investigate the sensitivity of the results to discount rates of 0% and 6%.  
 
Results 
Using the baseline values reported in Table 1, the estimated total cost over 5 years for a cohort of 
100 patients is £90,239 for strategy A and £87,360 for strategy B. The life years gained from each 
strategy are 256.47 and 255.73 respectively. This gives a cost per life year gained of immediate 
echocardiography of £3,897.  
This result is based on a large number of estimated parameter values and the point estimate is 
particularly sensitive to changes in some of the key parameters. The last two columns of Table 1 
report one-way sensitivity analysis using the lower and upper limits of each parameter. Of these 
estimates only one, using the lower limit for treatment benefits, is more than £6,500, and this 
value is still below the likely cost-effectiveness threshold cited in the NICE Technology Appraisal 
Guidance.27  
Sensitivity analyses were undertaken assuming that patients with heart failure who were 
mistakenly ‘ruled out’ using the BNP and ECG filter tests would, if still alive, return to their GP 
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(or be admitted to hospital) and receive ECG and an echocardiograph in due course when, and if, 
their symptoms deteriorated. If it is assumed that this would take place at 1 year after the initial 
tests the cost per QALY of immediate echocardiography rises to £8,250, rising to £16,750 if this 
occurred by 6 months after the initial tests. These calculations have conservatively assumed that 
patients whose symptoms deteriorated would have a similar prognosis to those treated at first 
presentation.   
 
Discussion  
The baseline estimate of cost per life year gained suggests that immediate echocardiography is 
cost effective. However, echocardiography facilities in the UK are currently in limited supply and 
appropriate and speedy referral for testing is a key issue. If the proportion of people being sent 
for tests that actually turn out to have heart failure is low, then immediate use of 
echocardiography becomes less cost effective, and waiting times will increase yet further. An 
advantage of both ECG and BNP testing is that they can be performed rapidly in a primary care 
setting, with results available within 20 minutes when using a near-patient testing assay, or next 
day from the local hospital biochemistry department. Therefore the use of these tests to filter out 
people who do not require an echocardiogram because of the very low likelihood of abnormality, 
can result in more efficient use of limited echocardiography facilities. ECG interpretation is now 
usually computerized, and need only be at the level of determining whether the trace is 
completely normal or not. Such targeted echocardiography has been recommended by NICE, 4 
after taking into consideration the current strain on echocardiographic facilities in the UK. Our 
analysis suggests that the economics support the clinical drive for greater availability of 
echocardiography for patients with suspected heart failure. 
 
Some qualifying remarks on the modelling assumptions are warranted. Firstly, we assume that the 
only value of echocardiography is in diagnosing heart failure. In fact echocardiography may 
provide information on underlying structural abnormalities of the heart that may not be the cause 
of symptoms but require further assessment or ongoing follow-up e.g. mild aortic stenosis. These 
additional benefits would increase the cost effectiveness of immediate echocardiography.  
 
Secondly, the model assumes that everyone who has a diagnosis of heart failure is eligible for 
treatment with ACE inhibitors and beta blockers. In reality even at the most specialised centres 
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only around 70% of patients will be able to tolerate a beta-blocker, and not all at the target doses 
used in clinical trials. This reduction in potential treatment benefits will reduce the cost 
effectiveness of immediate echocardiography: however, even with lower estimates of treatment 
effects this strategy is still cost-effective.  
 
   
 9 
 
Figure 1: Cost effectiveness schematic for 5 year period model 
 
 Events Important parameters 
1 GP suspects HF & requests tests 
(Two options A v B) 
‘prevalence’: the proportion of people sent 
for tests who actually have HF 
2 Strategy A Strategy B 
ECG and BNP for all 
then … 
 Echo and ECG 
for all 
Echo if BNP or ECG 
are T+ 
 
costs of tests 
sensitivity and specificity 
3 Test results* 
HF diagnosis 
No HF diagnosis
  
 
(T+, D+ and T+ D-) 
(T-, D+ and T- D-) 
 
 
False positives 
Missed cases   
4 Treatment (ACE inhibitors & b-blockers)  
for T+ 
Costs:  initiation and treatment 
Outcomes:  survival and hospitalisation  
* D+(-): positive (negative) for disease, T+(-): positive (negative) test 
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Table 1: Key parameters: baseline values, sensitivity analysis and data sources 
 
Parameter Baseline 
estimate 
Data source Sensitivity analysis 
   Parameter C/LYG (£) 
   Lower Upper Lower Upper 
Prevalence 29% Hillingdon9 18% 34% 6,430 3,288 
       
Diagnostic accuracy       
Echocardiography       
Sensitivity & Specificity 100% Gold standard  N/A N/A   
BNP & ECG        
Sensitivity 94% UK NP17  88 97 2,671 6,349 
Specificity 44%  37 51 3,238 4,556 
       
Costs of tests (£)       
Echocardiography 98 Ref Costs 0 196 -477 7,736 
12 lead ECG 65 Ref Costs N/A N/A     
BNP  12.5 Manufacturer 0 25 5,589 2,205 
         
Costs of drugs (£/year)         
ACE inhibitor 163  BNF 53 339 3,298 4,857 
Beta blocker 125  BNF  112 327 3,826 4,998 
Initiation and titration (£) 30 Ref Costs 0 100 3,841 4,029 
         
Hosp cost (£/bed day)   158 Ref Costs 122 193 3,991 3,806 
         
Treatment benefits         
% reduction in odds of 
death  (yrs 0,1,2,3,4) 
Yr 0: 20 
Yrs 1-4: 40 
Meta analyses 
(see text)  
Yr 0: 0 
Yrs 1-4: 10 
Yr 0: 30 
Yrs 1-4: 50  16,012 3,133 
% reduction in hosp. rate  18  0 30 4,974 3,179 
% reduction in length of 
stay 
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Meta analyses 
(see text) 
 
0 
 
20 4,155 3,123 
         
% already on ACE  20 UK NP17 0 30 4,133 3,779 
% already on b blocker 20 UK NP17  0 30 4,068 3,812 
         
Discount rate        
Costs 3.5 NICE 0 6 3,994 3,836 
Benefits 3.5 NICE 0 6 3,564 4,143 
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